MAPT and Alzheimer disease: A few studies have shown that high CSF ratio of tau/amyloid-β1–42 or phospho-tau/amyloid-β1–42 can discriminate patients with AD from those with bvFTD (or FTLD in general) (Rivero-Santana et al., 2017; Paterson et al., 2018).